Process for in vivo treatment of specific biological targets in bodily fluids

• US 8,105,793 B2
• Filed: 07/16/2008
• Issued: 01/31/2012
• Est. Priority Date: 03/07/2001
• Status: Expired due to Fees

• Current Assignee: Celltraffix, Inc.
• Original Assignee: Biomed Solutions, LLC
• Inventors: Connelly, Patrick R, Helfer, Jeffrey L, Custer, Andrew W, Kim, Michael B
• Primary Examiner(s): Chin, Chris L
• Application Number:
  US12/219,139
• Publication Number:
  US 20080286278A1
• Time in Patent Office: 1,294 Days
• Field of Search: None
• US Class Current: 435/7.2
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002

Abstract

A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent, wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.

Claims

1. A process for treating biological targets in a fluid of a biological organism, comprising

introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber with an inner diameter of 15 microns to 150 microns for conveying a flow of the fluid, the flow chamber having a capture zone comprising a target-specific binding agent,

wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.

2. The process of claim 1, wherein the assembly is implanted in a body.

3. The process of claim 1, wherein the assembly is present outside of a body.

4. The process of claim 1, wherein the fluid comprises blood, bone marrow, lymph, urine, bile, cerebral spinal fluid or a combination thereof.

5. The process of claim 1, wherein the biological target comprises a metastatic cancer cell, a stem cell or an immunological cell.

6. The process of claim 1, wherein the assembly comprises a stent, catheter, cannula, capsule, patch, wire, infusion sleeve, fiber, shunt or graft.

7. The process of claim 1, wherein the assembly is formed from a natural or synthetic polymer, fiber, diatomaceous earth, glass, metal, colloid or plastic.

8. The process of claim 1, wherein the target-specific binding agent comprises E-selectin, P-selectin, ICAM-1, cadherin-11 or a combination thereof.

9. The process of claim 1, wherein the target-specific binding agent is immobilized to a surface of the capture zone.

10. The process of claim 1, wherein after flux rolling of the biological target along the target-specific binding agent, the biological target is removed from the capture zone.

11. The process of claim 1, wherein after flux rolling of the biological target along the target-specific binding agent, the biological target is reintroduced to the fluid of the biological organism.

12. The process of claim 1, wherein the biological target passes through the assembly at least twice.

13. The process of claim 1, wherein the target-specific binding agent is adsorbed or covalently bonded to a surface of the capture zone.

14. The process of claim 1, wherein the capture zone further comprises an anti-proliferative agent, a toxic agent, a bio-active agent or a combination thereof, for neutralizing the biological target.

15. The process of claim 14, wherein the anti-proliferative agent, toxic agent, bio-active agent or combination thereof is adsorbed or covalently bonded to a surface of the capture zone.

16. A process for treating biological targets in a fluid of a biological organism, comprising

introducing an enriched fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber for conveying a flow of the fluid, and a capture zone comprising a target-specific binding agent,

wherein during flow of the fluid through the flow chamber, the biological target undergoes flux rolling along the target-specific binding agent.

17. A process for treating cellular targets in a blood sample of a human patient, comprising

introducing a blood sample comprising a cellular target to an assembly that is in fluid communication with a body of the human patient, the assembly comprising an inlet connected to receive the blood sample and an outlet connected to pass the blood sample from the assembly, wherein the assembly comprises a flow chamber with an inner diameter of 15 microns to 150 microns for conveying a flow of the blood sample, the flow chamber having a capture zone comprising a target-specific binding agent,

wherein during flow of the blood sample through the flow chamber, the cellular target undergoes flux rolling along the target-specific binding agent.

18. The process of claim 17, wherein the blood sample introduced to the assembly is enriched blood.

19. The process of claim 17, wherein the target-specific binding agent comprises E-selectin, P-selectin, ICAM-1, cadherin-11 or a combination thereof.